FindTrial
Sign In

Cabergoline As An Adjuvant To Clomiphene Citrate For Management Of Unexplained Infertility

Cabergoline As An Adjuvant To Clomiphene Citrate For Management Of Unexplained Infertility: Randomized Controlled Trial

Status
UNKNOWN
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03549741
Enrollment
120
Registered
2018-06-08
Start date
2018-07-31
Completion date
2019-11-30
Last updated
2018-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Brief summary

Infertility refers to an inability to conceive after having regular unprotected sex. Infertility can also refer to the biological inability of an individual to contribute to conception, or to a female who cannot carry a pregnancy to full term. In many countries infertility refers to a couple that has failed to conceive after 12 months of regular sexual intercourse

Interventions

DRUGClomiphene Citrate 50mg

oral tablets

DRUGCabergoline Oral Tablet

oral tablets

DRUGPlacebo Oral Tablet

oral tablets

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 35 Years
Healthy volunteers
No

Inclusion criteria

* unexplained infertility, Primary or secondary. * Absence of galactorrhoea. * Normal serum prolactin. * Normal hysterosalpingography. * Normal spermogram.

Exclusion criteria

* Women on other line of treatment as aromatase inhibitors,gonadotrophins, or tamoxifen. * Known hypersensitivity for cabergoline or clomiphene citrate. * Other factors of infertility as tubal factor, uterine factor or male factor.

Design outcomes

Primary

MeasureTime frameDescription
The number of mature follicles14 daysthe follicles reach the size of 18 mm

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026